Iptacopan Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 200mg
Reference Brands: Fabhalta (USA/EU)
Category: Immune Disorder
Iptacopan is an oral complement factor B inhibitor developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder in which red blood cells are destroyed by the immune system. By inhibiting factor B, Iptacopan prevents the activation of the alternative complement pathway, reducing hemolysis and improving hemoglobin levels. It is taken orally and offers a convenient alternative to intravenous complement inhibitors like eculizumab or ravulizumab. Iptacopan is available in Capsules and strengths such as 200mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Iptacopan is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Iptacopan can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Iptacopan is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes the destruction of red blood cells. It is also being studied for use in other complement-mediated diseases.
Iptacopan is made from a small-molecule selective inhibitor of complement factor B, which blocks the alternative complement pathway and prevents red blood cell destruction.
The trade name of Iptacopan is Fabhalta.
Iptacopan is made by Novartis Pharmaceuticals.
The generic name of the product is Iptacopan.
The brand name of Iptacopan is Fabhalta.
Iptacopan is manufactured by Novartis Pharmaceuticals in Switzerland and distributed globally.
Related Products
Sarilumab
Strength:
150 mg/1.14 mL, 200 mg/1.14 mL
Form: injection (prefilled syringe)
Reference Brands: Kevzara (USA/EU)
View Details
Quick Response Guaranteed | Verified Suppliers
